Abstract:The Vaccine Administration Law of the People's Republic of China and other relevant laws require that vaccine recipients or their guardians be educated about vaccines and how they work, and described in general the methods and contents of such vaccination education. With the new law and "Standard Operational Procedures for Immunization" as foundation documents, and in consultation with experts at home and abroad, the Chinese Preventive Medicine Association developed a consensus statement about informed consent for vaccination. This consensus statement is written for disease control and prevention health care personnel in vaccination services and describes the educational content of informed consent, a theoretical framework for immunization and immunization knowledge, the informed consent processes, principles of planning for vaccination, and an informed consent form. Part two of the consensus includes influenza vaccine, pneumococcal vaccine, haemophilus influenzae type b containing vaccine, enterovirus type 71 inactivated vaccine, rotavirus vaccine, varicella attenuated live vaccine, herpes-zoster vaccine, human papillomavirus vaccine, rabies vaccine, hemorrhagic fever with renal syndrome vaccine, leptospira vaccine, anthrax vaccine, hepatitis E vaccine, cholera vaccine, typhoid vaccine and tick-borne encephalitis vaccine.
[1] 中国疾病预防控制中心,国家免疫规划技术工作组流感疫苗工作组.中国流感疫苗预防接种技术指南(2020-2021)[J].中华流行病学杂志,2020,41(10):1555-1576.
[2] World Health Organization.Vaccines against influenza WHO position paper-November 2012[J].Wkly Epidemiol Rec,2012,87(47):461-476.
[3] 中华人民共和国国家卫生和计划生育委员会.流行性感冒诊疗方案(2018年版)[J].中华临床感染病杂志,2018,28(1):1-5.
[4] Mo Z,Nong Y,Liu S,et al.Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen,China[J].Hum Vaccin Immunother,2017,13(6):1-7.
[5] Moa AM,Chughtai AA,Muscatello DJ,et al.Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults:a systematic review and meta-analysis of randomised controlled trials[J].Vaccine,2016,34(35):4092-4102.
[6] Bekkat-Berkani R,Ray R,Jain VK,et al.Evidence update:GlaxoSmithKline's inactivated quadrivalent influenza vaccines[J].Expert Rev Vaccines,2016,15(2):201-214.
[7] He Xs,Holmes Th,Zhang C,et al.Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines[J].J Virol,2006,80(23):11756-11766.
[8] Mong KGI,Brokstad KA,Islam S,et al.Early induction of cross-reactive CD8+ T-cell responses in tonsils after live-attenuated influenza vaccination in children[J].J Infect Dis,2020,221(9):1528-1537.
[9] Lindsey BB,Jagne YJ,Armitage EP,et al.Effect of a russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia:an open-label,observational,phase 4 study[J].Lancet Respir Med,2019,7(8):665-676.
[10] Coelingh K,Olahide IR,Macdonald P,et al.Efficacy and effectiveness of live attenuated influenza vaccine in school-age children[J].Expert Rev Vaccines,2015,14(10):1331-1346.
[11] Feng S,Chiu SS,Chan ELY,et al.Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong:a test-negative case-control study[J].Lancet Respir Med,2018,6(12):925-934.
[12] Cate TR,Couch RB,Parker D,et al.Reactogenicity,immunogenicity,and antibody persistence in adults given inactivated influenza virus vaccines-1978[J].Rev Infect Dis,1983,5(4):737-747.
[13] Ochiai H,Shibata M,Kamimuar K,et al.Evaluation of the efficacy of split-product trivalent A(H1N1),A(H3N2),and B influenza vaccines:reactogenicity,immunogenicity and persistence of antibodies following two doses of vaccines[J].Microbiol Immunol,1986,30(11):1141-1149.
[14] Künzel W,Glathe H,Engelmann H,et al.Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time[J].Vaccine,1996,14(12):1108-1110.
[15] Song JY,Cheong HJ,Hwang IS,et al.Long-term immunogenicity of influenza vaccine among the elderly:risk factors for poor immune response and persistence[J].Vaccine,2010,28(23):3929-3935.
[16] Somes MP,Turner RM,Dwyer LJ,et al.Estimating the annual attack rate of seasonal influenza among unvaccinated individuals:a systematic review and meta-analysis[J].Vaccine,2018,36(23):3199-3207.
[17] Steinhoff MC,Omer SB,Roy E,et al.Influenza immunization in pregnancy-antibody responses in mothers and infants[J].N Engl J Med,2010,362(17):1644-1646.
[18] 孙树梅.关注儿童流感,重视疫苗接种——AAP感染性疾病委员会《儿童流感的预防与控制建议(2018—2019年)》解读[J].中国全科医学,2019,22(6):621-626.
[19] Demicheli V,Jefferson T,Ferroni E,et al.Vaccines for preventing influenza in healthy adults[J].Cochrane Database Syst Rev,2018,2:001269.
[20] 黄远东,赵晓平,万涛,等.慢性阻塞性肺病人群流感疫苗接种的效果观察[J].海南医学,2011,22(4):29-31.
[21] 高忠翠,李江涛,展胜.卡舒宁联合流感疫苗对老年性慢性支气管炎合并急性感染的防治效果[J].中国生物制品学杂志,2011,24(10):1214-1216.
[22] Vasileiou E,Sheikh A,Butler C,et al.Effectiveness of influenza vaccines in asthma:a systematic review and meta-analysis[J].Clin Infect Dis,2017,65(8):1388-1395.
[23] Clar C,Oseni Z,Flowers N,et al.Influenza vaccines for preventing cardiovascular disease[J].Cochrane Database Syst Rev,2015,(5):005050.
[24] Wang S,Zheng Y,Jin X,et al.Efficacy and safety of a live attenuated influenza vaccine in Chinese healthy children aged 3-17 years in one study center of a randomized,double-blind,placebo-controlled phase 3 clinical trial,2016/17 season[J].Vaccine,2020,38(38):5979-5986.
[25] Block SL,Heikkinen T,Toback SL,et al.The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children[J].Pediatr Infect Dis J,2011,30(3):203-207.
[26] 胡昱,李倩,陈雅萍,等.18岁以上人群接种四价流感病毒灭活疫苗免疫原性和安全性的Meta分析[J].国际流行病学传染病学杂志,2017,44(1):47-52.
[27] Pepin S,Dupuy M,Borja-Tabora CFC,et al.Efficacy,immunogenicity,and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35months:a multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres[J].Vaccine,2019,37(13):1876-1884.
[28] 武文娣,李克莉,许涤沙,等.中国2015—2018年3个流感季节流感疫苗疑似预防接种异常反应监测数据分析[J].中华预防医学杂志,2019,53(10):987-992.
[29] Vesikari T,Fleming DM,Aristegui JF,et al.Safety,efficacy,and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired,culture-confirmed influenza in young children attending day care[J].Pediatrics,2006,118(6):2298-2312.
[30] Bergen R,Black S,Shinefield H,et al.Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents[J].Pediatr Infect Dis J,2004,23(2):138-144.
[31] Redding G,Walker RE,Hessel C,et al.Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma[J].Pediatr Infect Dis J,2002,21(1):44-48.
[32] Piedra PA,Yan L,Kotloff K,et al.Safety of the trivalent,cold-adapted influenza vaccine in preschool-aged children[J].Pediatrics,2002,110(4):662-672.
[33] Belshe RB,Ambrose CS,Yi T.Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age[J].Vaccine,2008,26(Suppl 4):10-16.
[34] Block Sl,Yogev R,Hayden FG,et al.Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age[J].Vaccine,2008,26(38):4940-4946.
[35] Mallory RM,Yi T,Ambrose CS.Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age[J].Vaccine,2011,29(26):4322-4327.
[36] Vesikari T,Karvonen A,Korhonen T,et al.A randomized,double-blind study of the safety,transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine[J].Pediatr Infect Dis J,2006,25(7):590-595.
[37] Ezeanolue E,Harriman K,Hunter P,et al.General Best Practice Guidelines for Immunization[EB/OL].(2020-08-15)[2020-12-15].https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/.
[38] Grohskopf LA,Alyanak E,Broder KR,et al.Prevention and Control of Seasonal Influenza with Vaccines:Recommendations of the Advisory Committee on Immunization Practices-United States,2020-21 Influenza Season[J].MMWR Recomm Rep,2020,69(8):1-24.
[39] Grohskopf LA,Alyanak E,Broder KR,et al.Prevention and Control of Seasonal Influenza with Vaccines:Recommendations of the Advisory Committee on Immunization Practices-United States,2019-20 Influenza Season[J].MMWR RecommRep,2019,68(3):1-21.
[40] Chiavenna C,Presanis Am,Charlett A,et al.Estimating age-stratified influenza-associated invasive pneumococcal disease in England:a time-series model based on population surveillance data[J].PLoS Med,2019,16(6):1002829.
[41] 陈英虎,华春珍,俞蕙.儿童肺炎链球菌性疾病诊治与防控建议[J].中华儿科杂志,2018,56(8):564-570.
[42] Camargo DR,Pais FS,Volpini AC,et al.Revisiting molecular serotyping of Streptococcus pneumoniae[J].BMC Genomics,2015,16(5 Suppl):1.
[43] Taylor SN,Sanders CV.Unusual manifestations of invasive pneumococcal infection[J].Am J Med,1999,107(1A):12-27.
[44] Chi F,Leider M,Leendertz F,et al.New Streptococcus pneumoniae clones in deceased wild chimpanzees[J].J Bacteriol,2007,189(16):6085-6088.
[45] 王华庆,安志杰.肺炎球菌性疾病免疫预防专家共识(2017版)[J].中国预防医学杂志,2018,19(3):161-191.
[46] 李绍英,沈叙庄,王艳,等.5岁以下儿童门诊呼吸道感染常见病原携带及抗生素耐药的流行病学特征调查[J].中国实用儿科杂志,2004,19(4):212-216.
[47] 中华人民共和国卫生部.中国妇幼卫生事业发展报告(2011)[J].中国妇幼卫生杂志,2012,3(2):49-58.
[48] 刘又宁,陈民钧,赵铁梅,等.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8.
[49] 孙谨芳,么鸿雁,于石成,等.1990年和2010年中国3种细菌性脑膜炎疾病负担情况[J].疾病监测,2015,30(12):1008-1013.
[50] World Health Organization.Pneumococcal conjugate vaccines in infants and children under 5 years of age:WHO position paper-February 2019[J].Wkly Epidemiol Rec,2019,94(8):85-103.
[51] Lackner TE,Hamilton RG,Hill JJ,et al.Pneumococcal polysaccharide revaccination:immunoglobulin g seroconversion,persistence,and safety in frail,chronically ill older subjects[J].J Am Geriatr Soc,2003,51(2):240-245.
[52] Loughlin AM,Hsu K,Silverio AL,et al.Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children[J].Pediatr Infect Dis J,2014,33(5):504-510.
[53] 韦宁,安志杰,王华庆.中国≤18岁人群肺炎球菌相关病例中肺炎球菌血清型分布的系统评价[J].中国疫苗和免疫,2014,20(6):547-555.
[54] Shapiro ED,Berg AT,Austrian R,et al.The protective efficacy of polyvalent pneumococcal polysaccharide vaccine[J].N Eng J Med,1991,325(21):1453-1460.
[55] World Health Organization.Immunological basis for immunization series-module 9:haemophilus influenzae type b[R].Geneva:WHO,2009.
[56] Briere EC,Rubin L,Moro PL,et al.Prevention and control of haemophilus influenzae type b disease:recommendations of the advisory committee on immunization practices (ACIP)[J].MMWR Recomm Rep,2014,63(RR-01):1-14.
[57] Plotkin SA,Orenstein WA,Paul A,et al.Vaccines[M].6th edition.Philadelphia:ELSEVIER,2011.
[58] World Health Organization.Haemophilus influenzae type b (Hib) vaccination WHO position paper:July 2013-Recommendations[J].Vaccine,2013,31(52):6168-6169.
[59] Watt JP,Wolfson LJ,O'brien KL,et al.Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years:global estimates[J]. Lancet,2009,374(9693):903-911.
[60] Hamborsky J,Kroger A,Wolfe S.Epidemiology and prevention of vaccine-preventable diseases[M].13th Edition.Washington D.C.:Centers for Disease Control and Prevention,2015:199-133.
[61] 边兴艳,崔振泽,黄燕,等.大连地区儿童急性上呼吸道感染流感嗜血杆菌感染情况分析[J].中国卫生检验杂志,2007,17(1):117-118.
[62] Togashi T,Mitsuya N,Sumino S,et al.Safety,tolerability and immunogenicity of intramuscular administration of PRP-CRM197 Hib vaccine to healthy Japanese children:an open-label trial[J].Vaccine,2018,36(21):2968-2972.
[63] 李亚南,梁丽,李艳萍,等.A、C群脑膜炎球菌-b型流感嗜血杆菌多糖结合疫苗免疫学效果观察[J].中国生物制品学杂志,2012,25(9):1190-1194,1197.
[64] Li G,Zhang H,Zhou W,et al.Safety and immunogenicity of a diphtheria,tetanus,acellular pertussis and Haemophilus influenzae type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization[J].Vaccine,2010,28(25):4215-4223.
[65] 李艳萍,李凤祥,侯启明,等.中国婴幼儿接种吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌(结合)联合疫苗的安全性和免疫原性研究[J].中华流行病学杂志,2011,32(8):808-815.
[66] Obonyo CO,Lau J.Efficacy of Haemophilus influenzae type b vaccination of children:a meta-analysis[J].Eur J Clin Microbiol Infect Dis,2006,25(2):90-97.
[67] O'loughlin RE,Edmond K,Mangtani P,et al.Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine:systematic review[J].Vaccine,2010,28(38):6128-6136.
[68] Jackson C,Mann A,Mangtani P,et al.Effectiveness of Haemophilus influenzae type b vaccines administered according to various schedules:systematic review and meta-analysis of observational data[J].Pediatr Infect Dis J,2013,32(11):1261-1269.
[69] Fitzwater SP,Watt JP,Levine OS,et al.Haemophilus influenzae type b conjugate vaccines:considerations for vaccination schedules and implications for developing countries[J].Hum Vaccin,2010,6(10):810-818.
[70] 范仁锋,张吉凯,廖玉宜,等.2~71月龄儿童接种AC群脑膜炎球菌(结合)b型流感嗜血杆菌(结合)联合疫苗后不良事件观察[J].中国疫苗和免疫,2020,26(5):543-547.
[71] 邓新娅,李秀岭,魏章华,等.无细胞百白破b型流感嗜血杆菌联合疫苗大规模上市后安全性观察[J].中国疫苗和免疫,2018,24(2):182-185.
[72] 白云骅,李淑萍,丁舒,等.北京市朝阳区12 241名婴幼儿三个部位接种无细胞百白破b型流感嗜血杆菌联合疫苗安全性分析[J].中华预防医学杂志,2020,54(9):953-957.
[73] 李克莉,张丽娜,叶家楷,等.中国2017年疑似预防接种异常反应监测[J].中国疫苗和免疫,2020,26(1):9-18.
[74] Guan D,van der Sanden S,Zeng H,et al.Population dynamics and genetic diversity of C4 strains of human enterovirus 71 in Mainland China,1998-2010[J].PLoS One,2012,7(9):44386.
[75] 邓爱萍,张永慧,孙立梅,等.广东省健康人群手足口病病原隐性感染状况调查[J].中华流行病学杂志,2012,32(2):189-191.
[76] 张东晓,杨帆,王冰,等.深圳市社区人群EV71和CoxA16隐性感染的流行病学分析[J].中国热带医学,2011,11(11):1332-1333.
[77] Ho M,Chen Er,Hsu Kh,et al.An epidemic of enterovirus 71 infection in Taiwan.Taiwan Enterovirus Epidemic Working Group[J].N Engl J Med,1999,341(13):929-935.
[78] 安志杰,刘艳,廖巧红,等.肠道病毒71型灭活疫苗使用技术指南[J].中国疫苗和免疫,2016,22(4):458-464.
[79] Zhu F,Xu W,Xia J,et al.Efficacy,safety,and immunogenicity of an enterovirus 71 vaccine in China[J].N Engl J Med,2014,370(9):818-828.
[80] Zhu FC,Meng FY,Li JX,et al.Efficacy,safety,and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China:a multicentre,randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2013,381(9882):2024-2032.
[81] Li R,Liu L,Mo Z,et al.An inactivated enterovirus 71 vaccine in healthy children[J].N Engl J Med,2014,370(9):829-837.
[82] Hu YM,Wang X,Wang JZ,et al.Immunogenicity,safety,and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months[J].Clin Vaccine Immunol,2013,20(12):1805-1811.
[83] Liu L,Mo Z,Liang Z,et al.Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children:a report of further observations[J].BMC Med,2015,13(1):226.
[84] Mao Q,Wang Y,Shao J,et al.The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals[J].Hum Vaccin Immunother,2015,11(11):2723-2733.
[85] Zhang H,An D,Liu W,et al.Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay[J].PLoS One,2014,9(6):100545.
[86] Mao Q,Cheng T,Zhu F,et al.The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy Chinese infants and children[J].PLoS One,2013,8(11):79599.
[87] Estes MK.Rotaviruses and their replication[M].4th edition.Philadelphia:Lippincott-Raven,2001:747-1786.
[88] 蔡莎,朱庆雄.轮状病毒感染的研究进展[J].中国临床研究,2019,32(8):1132-1134.
[89] Estes MK,Cohen J.Rotavirus gene structure and function[J].Microbiol Rev,1989,53(4):410-449.
[90] Tallett S,Mackenzie C,Middleton P,et al.Clinical,laboratory,and epidemiologic features of a viral gastroenteritis in infants and children[J].Pediatrics,1977,60(2):217-222.
[91] Velazquez FR,Matson DO,Calva JJ,et al.Rotavirus infection in infants as protection against subsequent infections[J].N Engl J Med,1996,335(14):1022-1028.
[92] 杨海云.口服轮状病毒疫苗免疫效果及安全性研究文献综述[J].中外医疗,2014,33(6):186-188.
[93] Clements-Mann ML,Makhene MK,Mrukowicz J,et al.Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1,2,3 or 4 in adults,children and infants[J].Vaccine,1999,17(20-21):2715-2725.
[94] 代秋菊,许红梅.轮状病毒疫苗保护效果及其影响因素研究进展[J].儿科药学杂志,2019,25(12):51-56.
[95] 胡昱,陈雅萍,梁辉,等.口服人-牛(WC_3株)5价轮状病毒基因重配活疫苗保护效果的Meta分析[J].预防医学,2018,30(10):992-996,1001.
[96] World Health Organization.Rotavirus vaccines WHO position paper:January 2013-Recommendations[J].Vaccine,2013,31(52):6170-6171.
[97] 段招军,王华庆.儿童轮状病毒胃肠炎免疫预防专家共识(2020版)[J].中华预防医学杂志,2021,55(1):4-17.
[98] 蒋雪峰,郭林杰,钟梦婷,等.国产单价口服轮状病毒活疫苗保护效果分析[J].预防医学,2020,32(2):182-183,186.
[99] 黎明强,吕榜军,沈潘燕.口服轮状病毒活疫苗罗特威保护效果及安全性meta分析[J].中华疾病控制杂志,2015,19(10):1038-1041,1056.
[100] 洪荣涛.口服轮状病毒减毒活疫苗在婴幼儿人群使用中的挑战与对策[J].海峡预防医学杂志,2019,25(2):87-90.
[101] American Academy of Pediatrics.Red Book:2012 Report of the Committee on Infectious Diseases[M].Illinois:American Academy of Pediatrics,2012.
[102] 李兰娟,任红.传染病学[M].第九版.北京:人民卫生出版社,2018.
[103] Asano Y,Yazaki T,Miyata T,et al.Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection[J].Biken J,1975,18(1):35-40.
[104] Ceyhan M,Tezer H,Yildirim I.Secondary attack rate of hepatitis A,varicella and mumps in household settings and reliability of family history to detect seronegative children for necessity of vaccination[J].Scand J Infect Dis,2009,41(6-7):501-506.
[105] Centers for Disease Control and Prevention.Vaccine Information Statement-Varicella (Chickenpox) Vaccine[EB/OL].(2019-08-15)[2020-12-08].https://www.cdc.gov/vaccines/hcp/vis/current-vis.html.
[106] World Health Organization.Varicella and herpes zoster vaccines:WHO position paper,June 2014--Recommendations[J].Vaccine,2016,34(2):198-199.
[107] 随海田,李锦成,王淼,等.2005—2015年中国水痘流行病学特征[J].中国疫苗和免疫,2019,25(2):155-159.
[108] 殷大鹏,宋立志,张晓曙,等.鲁甘湘三省2007年水痘发病率调查[J].中国疫苗和免疫,2009,15(2):119-122.
[109] 李娜,方凯,马淑玲,等.国内水痘减毒活疫苗预防效果及其安全性的系统评价[J].中国疫苗和免疫,2012,18(1):54-60.
[110] 刘世科,王帆,章海斌,等.国产水痘减毒活疫苗不同时间加强免疫免疫原性观察[J].中国疫苗和免疫,2015,21(6):620-622.
[111] 孙海燕,袁家麟,刘骁.国产水痘减毒活疫苗接种的血清学免疫效果及成本效益分析[J].上海预防医学杂志,2003,15(9):445-447.
[112] 潘兴强,马瑞,方挺,等.接种1剂次水痘疫苗水痘突破病例发生率及疫苗效果[J].中华预防医学杂志,2015,49(7):611-614.
[113] Suo L,Lu L,Zhao D,et al.Impact of a 2-dose voluntary vaccination strategy on varicella epidemiology in Beijing,2011-2017[J].Vaccine,2020,38(20):3690-3696.
[114] 卢莉,索罗丹,李娟.北京市水痘疫苗使用技术指南[J].中华预防医学杂志,2013,47(1):67-69.
[115] 张军楠,黄卓英,王淼,等.中国水痘减毒活疫苗的安全性、免疫原性和保护效果[J].中国疫苗和免疫,2018,24(4):487-491.
[116] 中国医师协会皮肤科医师分会带状疱疹专家共识工作组.带状疱疹中国专家共识[J].中华皮肤科杂志,2018,51(6):403-408.
[117] 于生元,万有,万琪,等.带状疱疹后神经痛诊疗中国专家共识[J].中国疼痛医学杂志,2016,22(3):161-167.
[118] Kawai K,Gebremeskel BG,Acosta CJ.Systematic review of incidence and complications of herpes zoster:towards a global perspective[J].BMJ Open,2014,4(6):004833.
[119] Lu L,Suo L,Li J,et al.A retrospective survey on herpes zoster disease burden and characteristics in Beijing,China[J].Hum Vaccin Immunother,2018,14(11):2632-2635.
[120] Oxman MN.Zoster vaccine:current status and future prospects[J].Clin Infect Dis,2010,51(2):197-213.
[121] Cunningham Al,Heineman Tc,Lal H,et al.Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older[J].J Infect Dis,2018,217(11):1750-1760.
[122] Lal H,Cunningham AL,Godeaux O,et al.Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults[J].N Engl J Med,2015,372(22):2087-2096.
[123] Cunningham AL,Lal H,Kovac M,et al.Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older[J]. N Engl J Med,2016,375(11):1019-1032.
[124] Hastie A,Catteau G,Enemuo A,et al.Immunogenicity of the adjuvanted recombinant zoster vaccine:persistence and anamnestic response to additional doses administered 10 years after primary vaccination[J].J Infect Dis,2020.
[125] Godeaux O,Kovac M,Shu D,et al.Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥50 years of age with a prior history of herpes zoster:a phase III,non-randomized,open-label clinical trial[J].Hum Vaccin Immunother,2017,13(5):1051-1058.
[126] Bastidas A,de La Serna J,EI Idrissi M,et al.Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation:a randomized clinical trial[J].J Am Med Assoc,2019,322(2):123-133.
[127] Vink P,Ramon Torrell JM,Sanchez Fructuoso A,et al.Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant:a phase 3,randomized clinical trial[J].Clin Infect Dis,2020,70(2):181-190.
[128] Dagnew AF,Ilhan O,Lee WS,et al.Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies:a phase 3,randomised,clinical trial and post-hoc efficacy analysis[J].Lancet Infect Dis,2019,19(9):988-1000.
[129] Vink P,Delgado Mingorance I,Maximiano Alonso C,et al.Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors,vaccinated before or during chemotherapy:a randomized trial[J].Cancer,2019,125(8):1301-1312.
[130] Berkowitz EM,Moyle G,Stellbrink HJ,et al.Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults:a phase 1/2a randomized,placebo-controlled study[J].J Infect Dis,2015,211(8):1279-1287.
[131] Schwarz TF,Aggarwal N,Moeckesch B,et al.Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older[J].J Infect Dis,2017,216(11):1352-1361.
[132] Maréchal C,Lal H,Poder A,et al.Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age:a randomized trial[J].Vaccine,2018,36(29):4278-4286.
[133] Strezova A,Lal H,Enweonye I,et al.The adjuvanted recombinant zoster vaccine co-administered with a tetanus,diphtheria and pertussis vaccine in adults aged ≥50 years:a randomized trial[J].Vaccine,2019,37(39):5877-5885.
[134] Andersson S,Safari H,Mints M,et al.Type distribution,viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN)[J].Br J Cancer,2005,92(12):2195-2200.
[135] Tomaic V.Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites[J].Cancers (Basel),2016,8(10):95.
[136] Kjaer SK,Federiksen K,Munk C,et al.Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection:role of persistence[J].J Natl Cancer Inst,2010,102(19):1478-1488.
[137] Garland SM,Steben M,Sings HL,et al.Natural history of genital warts:analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6,11,16,and 18) vaccine[J].J Infect Dis,2009,199(6):805-814.
[138] de Martel C,Plummer M,Vignat J,et al.Worldwide burden of cancer attributable to HPV by site,country and HPV type[J].Int J Cancer,2017,141(4):664-670.
[139] Tovar JM,Bazaldua OV,Vargas L,et al.Human papillomavirus,cervical cancer,and the vaccines[J].Postgrad Med,2008,120(2):79-84.
[140] Alam S,Conway MJ,Chen HS,et al.The cigarette smoke carcinogen benzo[a] pyrene enhances human papillomavirus synthesis[J].J Virol,2008,82(2):1053-1058.
[141] Clifford GM,Smith JS,Plummer M,et al.Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis[J].Br J Cancer,2003,88(1):63-73.
[142] Zhang R,Velicer C,Chen W,et al.Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grades 1 or worse among 4,215 Chinese women in a population-based study[J].Cancer Epidemiol,2013,37(6):939-945.
[143] Zhu F,Li J,Hu Y,et al.Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years[J].Hum Vaccin Immunother,2014,10(7):1795-1806.
[144] Hu YM,Guo M,Li CG,et al.Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women[J].Sci China Life Sci,2020,63(4):582-591.
[145] Qiao YL,Wu T,Li RC,et al.Efficacy,safety,and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine:an interim analysis of a randomized clinical trial[J].J Natl Cancer Inst,2020,112(2):145-153.
[146] Li R,Li Y,Radley D,et al.Safety and immunogenicity of a vaccinetargeting human papillomavirus types 6,11,16 and 18:a randomized,double-blind,placebo-controlled trial in Chinese males and females[J].Vaccine,2012,30(28):4284-4291.
[147] Huang Z,He J,Su J,et al.Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years:a phase 3,open-label,immunobridging study[J].Vaccine,2021,39(4):760-766.
[148] Vesikari T,Brodszki N,van Damme P,et al.A randomized,double-blind,phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil(R) in 9-15-year-old girls[J].Pediatri Infect Dis J,2015,34(9):992-998.
[149] Joura EA,Giuliano AR,Iversen OE,et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J].N Engl J Med,2015,372(8):711-723.
[150] Garland SM,Pitisuttithum P,Ngan HYS,et al.Efficacy,immunogenicity,and safety of a 9-valent human papillomavirus vaccine:subgroup analysis of participants from Asian countries[J].J Infect Dis,2018,218(1):95-108.
[151] Zhu FC,Chen W,Hu YM, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial[J]. Int J Cancer, 2014, 135(11):2612-2622.
[152] Wei L,Xie X,Liu J,et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up[J]. Vaccine, 2019, 37(27):3617-3624.
[153] Drolet M, Bénard E, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis[J]. Lancet, 2019, 394(10197):497-509.
[154] Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer[J]. N Engl J Med, 2020, 383(14):1340-1348.
[155] Artemchuk H, Eriksson T, Poljak M, et al. Long-term antibody response to human papillomavirus vaccines: up to 12 years of follow-up in the Finnish maternity cohort[J]. J Infect Dis, 2019, 219(4):582-589.
[156] Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study[J]. Lancet, 2014, 384(9961):2213-2227.
[157] Schwarz TF, Huang LM, Medina DM, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years[J]. J Adolesc Health, 2012, 50(2):187-194.
[158] Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barre syndrome after human papilloma virus vaccine: a self-controlled case-series study in England[J]. Vaccine, 2017, 35(13):1729-1732.
[159] Gee J, Sukumaran L, Weintraub E, et al. Risk of Guillain-Barre syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink[J]. Vaccine, 2017, 35(43):5756-5758.
[160] Feiring B, Laake I, Bakken IJ, et al. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: a nationwide register-based study from Norway[J]. Vaccine, 2017, 35(33):4203-4212.
[161] Huygen F,Verschueren K, Mccabe C, et al. Investigating reports of complex regional pain syndrome: an analysis of HPV-16/18-adjuvanted vaccine post-licensure data[J]. EBioMedicine, 2015, 2(9):1114-1121.
[162] Brinth LS, Pors K, Theibel AC, et al. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus[J]. Vaccine, 2015, 33(22):2602-2605.
[163] Arana J,Mba-Jonas A,Jankosky C,et al. Reports of postural orthostatic tachycardia syndrome after human papillomavirus vaccination in the vaccine adverse event reporting system[J]. J Adolesc Health, 2017, 61(5):577-582.
[164] Schilling A, Parra MM, Gutierrez M, et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines[J]. Pediatrics, 2015, 136(3):17.
[165] Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects[J]. J Intern Med, 2014, 275(4):398-408.
[166] Heijstek MW, Scherpenisse M, Groot N, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study[J]. Ann Rheum Dis, 2014, 73(8):1500-1507.
[167] Jacobson DL, Bousvaros A, Ashworth L, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2013, 19(7):1441-1449.
[168] Toft L,Storgaard M,Muller M,et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial[J]. J Infect Dis, 2014, 209(8):1165-1173.
[169] Giacomet V,Penagini F,Trabattoni D,et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults[J]. Vaccine, 2014, 32(43):5657-5661.
[170] Baril L, Rosillon D, Willame C, et al. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom[J]. Vaccine, 2015, 33(48):6884-6891.
[171] Goss MA, Lievano F, Buchanan KM, et al. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine[J]. Vaccine, 2015, 33(29):3422-3428.
[172] World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017[J]. Wkly Epidemiol Rec, 2017, 92(19):241-268.
[173] 中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识[J]. 中华预防医学杂志, 2019, 53(8):761-803.
[174] The International Committee on Taxonomy of Viruses. Rhabdoviridae[EB/OL]. (2020-04-05)[2020-04-05]. https: //talk. ictvonline. org/ictvreports/ictv_9th_report/negative-sense-rna-viruses-2011/w/negrna_viruses/201/rhabdoviridae.
[175] Mclean HQ, World Health Organization. The immunological basis for immunization series: module 17: rabies[M]. Geneva: WHO, 2011.
[176] World Health Organization. WHO expert consultation on rabies[R]. Geneva: WHO, 2013.
[177] World Health Organization. WHO fact sheet on rabies[EB/OL]. (2020-04-05)[2020-12-08]. http://www.who.int/mediacentre/factsheets/ fs099/ en/.
[178] Hampson K, Coudeville L, Lembo T, et al. Correction: estimating the global burden of endemic canine rabies[J]. PLoS Negl Trop Dis, 2015, 9(5):e0003786.
[179] Dodet B,Africa Rabies Expert B,Adjogoua EV,et al. Fighting rabies in Africa: the Africa Rabies Expert Bureau (AfroREB)[J]. Vaccine, 2008, 26(50):6295-6298.
[180] Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia[J]. Bull World Health Organ, 2005, 83(5):360-368.
[181] Birhane MG, Cleaton JM, Monroe BP, et al. Rabies surveillance in the United States during 2015[J]. J Am Vet Med Assoc, 2017, 250(10):1117-1130.
[182] Rupprecht CE, Nagarajan T, Ertl H. Current status and development of vaccines and other biologics for human rabies prevention[J]. Expert Rev Vaccines, 2016, 15(6):731-749.
[183] World Health Organization. The immunological basis for immunization series: module 17: rabies vaccines [EB/OL].(2017-11-01)[2020-12-05]. http://www.who.int/immunization/documents/policies/WHO_IVB_ISBN9789241513371/en.
[184] Franka R,Wu X,Jackson FR,et al. Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines[J]. Vaccine, 2009, 27(51):7149-7155.
[185] Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices[J]. MMWR Recomm Rep, 2010, 59(RR-2):1-9.
[186] Hu Q,Liu MQ,Zhu ZG,et al. Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China[J]. Hum Vaccin Immunother, 2014, 10(6):1645-1649.
[187] Huang G, Liu H, Tang Q, et al. Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers[J]. Hum Vacc Immunother, 2014, 10(1):114-119.
[188] Wasi C, Chaiprasithikul P, Auewarakul P, et al. The abbreviated 2-1-1 schedule of purified chick embryo cell rabies vaccination for rabies postexposure treatment[J]. Southeast Asian J Trop Med Public Health, 1993, 24(3):461-466.
[189] 陈恩富,王臻,胡建锦,等.国产纯化Vero细胞狂犬病疫苗暴露前免疫效果观察[J].中华流行病学杂志,2009,30(1):33.
[190] World Health Organization.Rabies vaccines: WHO position paper--recommendations[J].Vaccine,2010,28(44):7140-7142.
[191] 中国疾病预防控制中心.狂犬病预防控制技术指南(2016版)[J].中国病毒病杂志,2016,6(3):161-188.
[192] Manning SE,Rupprecht CE,Fishbein D,et al.Human rabies prevention-United States,2008: recommendations of the Advisory Committee on Immunization Practices[J].MMWR Recomm Reports,2008,57(RR-3):1-27.
[193] Simons FER,Ardusso LRF,Bilò MB,et al.2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis[J].Cur Opin Allergy Clin Immunol,2012,12(4):389-399.
[194] Fishbein DB,Yenne KM,Dreesen DW,et al.Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study[J].Vaccine,1993,11(14):1390-1394.
[195] 中华人民共和国卫生部.过敏性紫癜等6种疾病诊疗指南[S].2010-09-18.
[196] 史建伟,彭芝英,汤卫平,等.狂犬病疫苗接种后不良反应观察研究[J].实用预防医学,2006,13(6):1515-1516.
[197] 苏雪媚,李文东.狂犬疫苗致不良反应156例文献分析[J].中国药房,2009,20(17):1348-1350.
[198] 黄肖梅.人用狂犬病疫苗不良反应的调查报告[J].海峡药学,2010,22(4):178-179.
[199] Abazeed ME,Cinti S.Rabies prophylaxis for pregnant women[J].Emerging Infect Dis,2007,13(12):1966-1967.
[200] 陈化新.中国肾综合征出血热疫苗大规模应用研究[J].中华流行病学杂志,2002,23(2):70-72.
[201] 陈化新,罗兆庄,张家驹,等.肾综合征出血热疫苗预防效果和免疫策略研究[J].中国公共卫生,1999,15(7):3-10.
[202] 董关木.肾综合征出血热疫苗研究现状[J].中华实验和临床病毒学杂志,2003,17(2):96-100.
[203] 王玉林,罗兆庄.中国肾综合征出血热疫苗的研究[J].中国媒介生物学及控制杂志,2003,14(5):398-399.
[204] 陈化新,叶克龙,张家驹,等.中国肾综合征出血热疫苗免疫效果评价和免疫策略研究[J].中国媒介生物学及控制杂志,1996,7(4):241-247.
[205] Jung J,Ko SJ,Oh HH,et al.Protective effectiveness of inactivated hantavirus vaccine against hemorrhagic fever with renal syndrome[J].J Infect Dis,2018,217(9):1417-1420.
[206] 王鸣.实用免疫接种培训教程[M].北京: 中国中医药出版社,2007:115-222.
[207] 李凡,徐志凯.医学微生物学[M].北京: 人民卫生出版社,2013: 198-202.
[208] 严杰,戴保民,于恩庶.钩端螺旋体病学[M].北京: 人民卫生出版社,2006: 471-476.
[209] Faine S,Adler B,Bolin C,et al.Leptospira and Leptospirosis[M].2nd edition.Melbourne: MediSci,1999:121.
[210] 中华人民共和国国家药典委员会.中华人民共和国药典(三部)[M].北京: 中国医药科技出版社,2015:121-151.
[211] 支慧,王克霞,李朝品.钩端螺旋体疫苗的研究现状[J].中国媒介生物学及控制杂志,2005,16(1):71-73.
[212] 谢广中,张锦麟,秦进才,等.钩端螺旋体外膜疫苗的反应性和免疫效果研究[J].微生物学免疫学进展,2002,30(2):14-18.
[213] 徐国英,潘敏楠,林光宇,等.福建省新丙五价钩端螺旋体菌苗接种后反应与免疫效果的观察[J].中国人兽共患病杂志,2005,21(11):96-99.
[214] 严有望.钩端螺旋体疫苗大面积接种的流行病学效果[J].中国生物制品学杂志,2000,13(3):188-189.
[215] 秦进才,高吉元,蒲丛.钩端螺旋体疫苗的接种反应和血清学效果观察[J].微生物学杂志,2004,24(5):26-28.
[216] 刁连东,孙晓东.实用疫苗学[M].上海: 上海科学技术出版社,2015: 326-330.
[217] 寇志华,魏茂提,张松乐,等.炭疽疫苗A16R诱导小鼠的黏膜与系统免疫应答[J].中国生物制品学杂志,2003,5(5):273-275.
[218] 董树林.新中国炭疽防治成果与研究进展[J].中华流行病学杂志,1999,20(3):8-10.
[219] 李澄,闫绍宏,郭卫东,等.2001-2011年内蒙古炭疽流行病学特征分析[J].中国人兽共患病学报,2012,28(8):854-856.
[220] World Health Organization.Hepatitis E vaccine: WHO position paper,May 2015-Recommendations[J].Vaccine,2016,34(3):304-305.
[221] 孙校金,张国民,郑徽,等.2004—2017年中国戊型肝炎流行特征分析[J].中华预防医学杂志,2019,53(4):382-387.
[222] Jia Z,Yi Y,Liu J,et al.Epidemiology of hepatitis E virus in China: results from the Third National Viral Hepatitis Prevalence Survey,2005-2006[J].PloS One,2014,9(10):e110837.
[223] 王富珍,孙校金,王锋,等.我国2014年1~29岁人群戊型肝炎血清流行病学特征分析[J].中华流行病学杂志,2019,40(11):1426-1427,1431.
[224] Yu XY,Chen ZP,Wang SY,et al.Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years[J].Vaccine,2019,37(32):4581-4586.
[225] Zhu FC,Zhang J,Zhang XF,et al.Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale,randomised,double-blind placebo-controlled,phase 3 trial[J]. Lancet,2010,376(9744):895-902.
[226] Zhang J,Zhang XF,Huang SJ,et al.Long-term efficacy of a hepatitis E vaccine[J].NEJM,2015,372(10):914-922.
[227] Albert MJ,Ansaruzzaman M,Bardhan PK,et al.Large epidemic of cholera-like disease in Bangladesh caused byVibrio cholerae O139 synonym Bengal[J]. Lancet,1993,342(8868):387-390.
[228] Ramamurthy T,Garg S,Sharma R,et al.Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India[J]. Lancet,1993,341(8846):703-704.
[229] Johnson JA,Salles CA,Panigrahi P,et al.Vibrio cholerae O139 synonym Bengal is closely related to Vibrio cholerae El Tor but has important differences[J].Infect Immun,1994,62(5):2108-2110.
[230] Carpenter CC.Cholera: diagnosis and treatment[J].Bull N Y Acad Med,1971,47(10):1192-1203.
[231] Koch R.An address on cholera and its bacillus[J].Br Med J,1884,2(1235):403-407.
[232] Howard-Jones N.Robert Koch and the cholera vibrio: a centenary[J].Br Med J (Clin Res Ed),1984,288(6414):379-381.
[233] Lowry PW,Pavia AT,Mcfarland LM,et al.Cholera in Louisiana.Widening spectrum of seafood vehicles[J].Arch Intern Med,1989,149(9):2079-2084.
[234] Svennerholm AM,Jertborn M,Gothefors L,et al.Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine[J].J Infect Dis,1984,149(6):884-893.
[235] Sack DA,Clemens JD,Huda S,et al.Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh[J]. J Infect Dis,1991,164(2):407-411.
[236] Svennerholm AM,Holmgren J.Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid[J].Infect Immun,1976,13(3):735-740.
[237] 陈清,俞守义,王雅贤,等.冻干口服霍乱rBS—WC菌苗安全性及免疫原性的人群试验[J].中华预防医学杂志,1996,30(6):330-333.
[238] 甄蓓,俞守义,陈清,等.冻干口服霍乱rBS—WC疫苗现场试验及评价[J].中国计划免疫,1999,5(4):210-214.
[239] Sanchez JL,Trofa AF,Taylor DN,et al.Safety and immunogenicity of the oral,whole cell/recombinant B subunit cholera vaccine in North American volunteers[J].J Infect Dis,1993,167(6):1446-1449.
[240] Begue RE,Castellares G,Ruiz R,et al.Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru[J].Vaccine,1995,13(7):691-694.
[241] 时念民,罗凤基,李书明,等.大学生与务工人员服用口服重组B亚单位霍乱疫苗的安全性及效果分析[J].中华医学杂志,2010,90(3):192-195.
[242] 黄腾,李荣成,刘德平.重组B亚单位/菌体霍乱疫苗以抗酸剂冲服对2~6岁健康人群的免疫原性和安全性研究[J].中华预防医学杂志,2017,51(9):827-831.
[243] 张鑫培,陈恩富,吕华坤,等.自然人群口服重组B亚单位/菌体霍乱疫苗现场安全性评价[J].中国疫苗和免疫,2009,15(3):255-258.
[244] 贾蕾,吴疆,黎新宇,等.口服霍乱菌苗安全性评价[J].现代预防医学,2007,34(1):128-130.
[245] Fuerst HT.Typhoid fever and other Salmonella infections[J].Postgrad Med J,1964,40(462):223-223.
[246] Ewing WH.Edwards and Ewing's identification of enterobacteriaceae[M].4th Edition.NewYork: Elsevier, 1986.
[247] Brown KW,Donnelly KC,Deuel L.Effects of mineral nutrients,sludge application rate,and application frequency on biodegradation of two oily sludges[J].Microb Ecol,1983,9(4):363-373.
[248] 曲梅,黄瑛,张新,等.2008—2018年北京市伤寒、副伤寒沙门菌病原学特征[J].首都公共卫生,2019,13(2):57-61.
[249] 艾敏,王树坤.全球伤寒与副伤寒流行情况、危险因素和预防策略[J].中国公共卫生,2019,35(2):250-256.
[250] Immunization Action Coalition.Vaccine information statements[EB/OL].(2020-11-19)[2020-12-08].http://www.immunize.org/vis.
[251] Bhutta ZA.Impact of age and drug resistance on mortality in typhoid fever[J].Arch Dis Child,1996,75(3):214-217.
[252] 周伟忠,张亮才,倪大新,等.国产与法国Merieux产伤寒Vi多糖菌苗人体接种反应与血清学效果观察[J].中国公共卫生,1999,15(10):3-5.
[253] 周伟忠,曾明,潘红星,等.伤寒Vi多糖疫苗的接种反应及其免疫效果[J].中国生物制品学杂志,2008,21(5):425-427.
[254] Acosta CJ,Deng Q,Zhou BD,et al.Efficacy of a locally produced,Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up[J].Vaccine,2005,23(48-49):5618-5623.
[255] Yang HH,Kilgore PE,Yang LH,et al.An outbreak of typhoid fever,Xing-an County,People's Republic of China,1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine[J].J Infect Dis,2001,183(12):1775-1780.
[256] 王志高,周伟忠,程信超,等.伤寒Vi多糖菌苗人体接种反应与血清学观察[J].江苏预防医学,1996,(4):12-14.
[257] 何莓,王惟信,华羚,等.伤寒的现状分析及预防控制[J].中国国境卫生检疫杂志,2012,35(6):425-428.
[258] 邱宇鹤,王轶文,何淑云.森林脑炎疫苗的研究进展[J].中国生物制品学杂志,2015,28(11):1228-1230,1232.
[259] 何淑云,付博,范学斌,等.森林脑炎灭活疫苗的安全性和免疫原性研究[J].中国实验诊断学,2014,18(5):810-811.
[260] 刘双军,刘岩松,孙宏亮,等.不同病毒培养方式制备森林脑炎灭活疫苗的比较[J].中国生物制品学杂志,2018,31(5):449-452.
[261] 杜瑞林,宋宗明,刘国云,等.森林脑炎灭活疫苗大规模人群接种的接种反应及免疫效果观察[J].中国生物制品学杂志,2012,25(11):1511-1513.
[262] 周凤岩,付博,乔建国,等.不同年龄人群免疫森林脑炎灭活疫苗后28d免疫效果观察[J].中国卫生工程学,2013,12(6):504-505,507.
[263] 李文娟,张颖,孙宏亮,等.两种不同培养工艺制备森林脑炎灭活疫苗的免疫原性及安全性评价[J].中国生物制品学杂志,2020,33(3):246-249.
[264] 费刚.森林脑炎灭活疫苗细菌内毒素含量的测定[J].中国医药指南,2013,11(25):356-357.
[265] 刘长胜,范晓宇.注射森林脑炎灭活疫苗致过敏性休克1例[J].临床军医杂志,2013,41(11):1210.
[266] 何淑云,王轶文,乔建国,等.森林脑炎灭活疫苗加强免疫效果的临床观察[J].中国生物制品学杂志,2015,28(4):377-378.